Medical devices, healthcare technology and the business of care
510(k) clearance · K262151

SpaceOAR Flex System

BOSTON SCIENTIFIC CORPORATION · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONK262151

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K262151, the SpaceOAR Flex™ System, on September 11, 2026, with the submission received June 25, 2026. The applicant is Boston Scientific Corporation; the device falls under 21 CFR 892.5725 (absorbable perirectal spacer), Class II, product code OVB, in the Radiology specialty. SESE in a 510(k) is a clearance, not a PMA approval.

The subject device is a sterile, single-use PEG hydrogel spacer supplied as two pre-filled glass syringes with a luer connector and a separately pouched 18 G x 15 cm needle; the hydrogel is polymerized during manufacturing. The listed predicate is the SpaceOAR Vue™ System (K182971, cleared July 19, 2019), with identical indications for use and principles of operation. The summary table records differences in components, sterilization (moist heat and X-ray versus gamma) and shelf life (18 versus 24 months). The source does not state the basis for the clinical trial identifier listed on the FDA page.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Sep 11, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262151
Regulatory pathway
510(k) premarket notification
Product code
OVB
Decision code
SESE
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hydrogel Spacer.

Product code
OVB
FDA device class
2

FDA decision timeline

  1. K262151 received

    Application receipt date recorded by FDA.

  2. K262151 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
Marlborough, MA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records